High-risk factors for AIHA in CLL patients include progressive disease, advanced age, small-ploidy lymphocytes, high level of beta-2 microglobulin, cytogenetic abnormalities, and non-mutations of the IGHV gene15. The gene discussed is B2M; the disease is autoimmune hemolytic anemia.